The University of Southampton
University of Southampton Institutional Repository

New strategies in the treatment and prevention of allergic diseases

New strategies in the treatment and prevention of allergic diseases
New strategies in the treatment and prevention of allergic diseases
Allergic diseases (AD) are more prevalent today than 30 years ago but over the same period, few novel efficacious drugs have been discovered to treat, control or even cure these disorders.
Topical or systemic glucocorticosteroids combined with symptom-relieving medications, such as ?2-adrenoceptor agonists, leukotriene inhibitors or antihistamines, are still the mainstay of antiallergic treatment. Modified glucocorticosteroids with less adverse effects, better bronchodilators and new selective mediator inhibitors may improve symptom control in the future. Only specific immunotherapy has shown potential for long-lasting disease-modifying effects.
Immunomodulation is a therapeutic goal, aiming to modify the dominant helper T cell Type 2 inflammation to a helper T cell Type 1 response using modified allergens, mycobacteria or CpG oligodeoxynucleotides. Humanised monoclonal anti-IgE antibodies are an exciting new immunomodulatory medication that are expected to reach the clinical practice and have recently been licensed in Australia and the US.
Advances in molecular, cellular and genetic research of the immunopathophysiology of AD have led to the development of new antagonists for cytokines, chemokines, receptors, second messengers and transcription factors that may become available for clinical use in the next 10 years. Specific diets supplemented with antioxidants or probiotics need further study but offer promise as safe and cheap preventative medicine.
The strong genetic component of AD and the Human Genome Project have opened a new field of research, and modification or replacement of target genes has a curative potential with exciting new therapeutic developments in the years ahead.
allergic conjunctivitis, allergic dermatitis, allergic rhinitis, anti-inflammatory, antioxidants, antisense, asthma, atopy, ?2-adrenoceptor, chemokines, cytokines, food allergy, genetics, glucocorticosteroids, histamine, Ige, immunomodulation, immunosuppression, immunotherapy, kinins, leukotrienes, mast cell, mediators, mycobacterium, new agents, nitric oxide, oligodeoxynucleotide, oxidative stress, phosphodiesterase, probiotics, proteases, rna interference, sirna, stem cells, therapy, treatment, urticaria
1354-3784
107-124
Haitchi, H.M.
68dadb29-305d-4236-884f-e9c93f4d78fe
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Haitchi, H.M.
68dadb29-305d-4236-884f-e9c93f4d78fe
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc

Haitchi, H.M. and Holgate, S.T. (2004) New strategies in the treatment and prevention of allergic diseases. Expert Opinion on Investigational Drugs, 13 (2), 107-124.

Record type: Article

Abstract

Allergic diseases (AD) are more prevalent today than 30 years ago but over the same period, few novel efficacious drugs have been discovered to treat, control or even cure these disorders.
Topical or systemic glucocorticosteroids combined with symptom-relieving medications, such as ?2-adrenoceptor agonists, leukotriene inhibitors or antihistamines, are still the mainstay of antiallergic treatment. Modified glucocorticosteroids with less adverse effects, better bronchodilators and new selective mediator inhibitors may improve symptom control in the future. Only specific immunotherapy has shown potential for long-lasting disease-modifying effects.
Immunomodulation is a therapeutic goal, aiming to modify the dominant helper T cell Type 2 inflammation to a helper T cell Type 1 response using modified allergens, mycobacteria or CpG oligodeoxynucleotides. Humanised monoclonal anti-IgE antibodies are an exciting new immunomodulatory medication that are expected to reach the clinical practice and have recently been licensed in Australia and the US.
Advances in molecular, cellular and genetic research of the immunopathophysiology of AD have led to the development of new antagonists for cytokines, chemokines, receptors, second messengers and transcription factors that may become available for clinical use in the next 10 years. Specific diets supplemented with antioxidants or probiotics need further study but offer promise as safe and cheap preventative medicine.
The strong genetic component of AD and the Human Genome Project have opened a new field of research, and modification or replacement of target genes has a curative potential with exciting new therapeutic developments in the years ahead.

This record has no associated files available for download.

More information

Published date: 2004
Keywords: allergic conjunctivitis, allergic dermatitis, allergic rhinitis, anti-inflammatory, antioxidants, antisense, asthma, atopy, ?2-adrenoceptor, chemokines, cytokines, food allergy, genetics, glucocorticosteroids, histamine, Ige, immunomodulation, immunosuppression, immunotherapy, kinins, leukotrienes, mast cell, mediators, mycobacterium, new agents, nitric oxide, oligodeoxynucleotide, oxidative stress, phosphodiesterase, probiotics, proteases, rna interference, sirna, stem cells, therapy, treatment, urticaria

Identifiers

Local EPrints ID: 27084
URI: http://eprints.soton.ac.uk/id/eprint/27084
ISSN: 1354-3784
PURE UUID: 2f4a3c1b-4730-48c1-beb5-7d8f33f7b21f
ORCID for H.M. Haitchi: ORCID iD orcid.org/0000-0001-8603-302X

Catalogue record

Date deposited: 26 Apr 2006
Last modified: 23 Jul 2022 01:50

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×